<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02523976</url>
  </required_header>
  <id_info>
    <org_study_id>IHBDH-IIT2015001</org_study_id>
    <nct_id>NCT02523976</nct_id>
  </id_info>
  <brief_title>Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Dasatinib Plus Multi-agent Chemotherapy for New Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Hematology &amp; Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Hematology &amp; Blood Diseases Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this single-center, open-label, no control,prospective clinical trial, a total of 30&#xD;
      Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients will be&#xD;
      enrolled. Dasatinib 100 mg per day will be given orally along with combination chemotherapy&#xD;
      starting day 8 of induction chemotherapy. Dasatinib will be given continuously (if it's&#xD;
      tolerable) for 2 years since achievement of complete remission (CR) as part of consolidation&#xD;
      chemotherapy and maintenance therapy.Patients can receive allogeneic hematopoietic stem cell&#xD;
      transplantation (HSCT) or autologous HSCT whenever possible during their first CR. Otherwise,&#xD;
      they will finish the consolidation chemotherapy. The purpose of current study is to determine&#xD;
      the clinical efficacy and tolerability of combination therapy of Dasatinib with multi-agent&#xD;
      chemotherapy in newly-diagnosed Ph+ ALL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this single-center, open-label, Phase II study, nonrandomized,no control,prospective&#xD;
      clinical trial,a total of 30 Philadelphia chromosome-positive acute lymphoblastic leukemia&#xD;
      (Ph+ALL) patients will be enrolled.Patients will be diagnosed according to&#xD;
      morphologic,immunologic, cytogenetic and molecular(MICM) criteria, including bone marrow&#xD;
      morphology, immunophenotype, cytogenetic and molecular genetic (BCR/ABL gene, qualitative and&#xD;
      quantitative analysis) examination.&#xD;
&#xD;
      Dasatinib 100 mg per day will be given orally along with combination chemotherapy starting&#xD;
      day 8 of induction chemotherapy. Dasatinib will be given continuously (if it's tolerable) for&#xD;
      2 years since achievement of complete remission (CR) as part of consolidation chemotherapy&#xD;
      and maintenance therapy.Patients can receive allogeneic hematopoietic stem cell&#xD;
      transplantation (HSCT),or patients who keep BCR/ABL negative can receive autologous HSCT&#xD;
      whenever possible during their first CR. Otherwise, they will finish the consolidation&#xD;
      chemotherapy. Total duration of follow-up will be 2 year after last enrollment.&#xD;
&#xD;
      Pre-treatment evaluation will include complete blood count (CBC) with reticulocyte count,&#xD;
      chemistry, electrolytes, coagulation, hepatitis profile, chest X-ray.Evaluation during&#xD;
      treatment will include: CBC every two days during myelosuppression, chemistry, electrolytes,&#xD;
      coagulation before each cycles of chemotherapy. Quantitative PCR (RQ-PCR) for Bcr-Abl will be&#xD;
      done from bone marrow mononuclear cells at diagnosis, at CR, and before each cycles of&#xD;
      consolidation chemotherapy,then every 3 months during maintenance therapy. For patients who&#xD;
      undergo allogeneic HSCT, quantitative PCR for Bcr-Abl will be done from bone marrow&#xD;
      mononuclear cells at the initiation of conditioning, and then every 3 months. PCR will be&#xD;
      done in IS standardized lab.&#xD;
&#xD;
      Side effects of combination therapy will be monitored and described according to Common&#xD;
      Toxicity Criteria, version 4.0 (National Cancer Institute, USA).&#xD;
&#xD;
      The purpose of current study is to determine the clinical efficacy and tolerability of&#xD;
      combination therapy of Dasatinib with multi-agent chemotherapy in newly-diagnosed Ph+ ALL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From date of diagnosis until the date of death from any cause, assessed up to 60 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>From the date of complete remission(CR) until the date of documented relapse,assessed up to 60 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The complete remission (CR) rate</measure>
    <time_frame>Participants will be followed for the duration of the treatment, an expected average of 6 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The molecular CR rate</measure>
    <time_frame>Participants will be followed for the duration of the treatment, an expected average of 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The plasma level of dasatinib in the regimen</measure>
    <time_frame>Up to 3 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Cerebrospinal fluid level of dasatinib in the regimen</measure>
    <time_frame>Up to 6 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse event of combined treatment</measure>
    <time_frame>Participants will be followed for the duration of the treatment, an expected average of 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade of adverse event of combined treatment</measure>
    <time_frame>Participants will be followed for the duration of the treatment, an expected average of 24 months.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Acute,Leukemia, Lymphoid</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasatinib 100 mg per day will be given orally along with combination chemotherapy starting day 8 of induction chemotherapy. Dasatinib will be given continuously (if it's tolerable) for 2 years since achievement of complete remission (CR) as part of consolidation chemotherapy and maintenance therapy.Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT),or patients who keep BCR/ABL negative can receive autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>Second-generation tyrosine kinase inhibitor</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mercaptopurine</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous hematopoietic stem cell transplantation</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 18 to 60 years with De novo Philadelphia chromosome positive&#xD;
             (Philadelphia chromosome positive or BCR/ABL transcript positive) acute lymphoblastic&#xD;
             leukemia.&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) Performance status 2.&#xD;
&#xD;
          3. Adequate end organ function as defined by: Total bilirubin ≤ 1.5 x upper limit of&#xD;
             normal（ULN）; serum glutamic-oxaloacetic transaminase(SGOT) and serum glutamic pyruvic&#xD;
             transaminase(SGPT) ≤ 2.5 x ULN; Creatinine ≤ 1.5 x ULN; Serum amylase and lipase ≤ 1.5&#xD;
             x ULN; Alkaline phosphatase ≤ 2.5 x ULN unless considered tumor related; Patients must&#xD;
             have adequate cardiac function (ejection fraction ≥ 45 % on Multiple Gated Acquisition&#xD;
             (MUGA) scan).&#xD;
&#xD;
          4. Patients must have the following laboratory values (≥ lower limit of normal (LLN) or&#xD;
             corrected to within normal limits with supplements prior to the first dose of study&#xD;
             medication.): Potassium ≥ LLN; Magnesium ≥ LLN; Phosphorus ≥ LLN&#xD;
&#xD;
          5. Patients should sign informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Impaired cardiac function:&#xD;
&#xD;
             Long QT syndrome or a known family history of long QT syndrome; clinically significant&#xD;
             resting brachycardia (&lt;50 beats per minute); ejection fraction &lt; 45 % on MUGA scan.&#xD;
             QTc interval &gt; 450 msec on baseline ECG (using the QTcF formula). If QTcF interval&gt;450&#xD;
             msec and electrolytes are not within normal ranges, electrolytes should be corrected&#xD;
             and then the patient re-screened for QTc. Myocardial infarction within 12 months prior&#xD;
             to starting study; other clinically significant heart disease (e.g. unstable angina,&#xD;
             congestive heart failure or uncontrolled hypertension, uncontrolled arrhythmias).&#xD;
&#xD;
             Patients who are currently receiving treatment with any medications that have the&#xD;
             potential to prolong the QT interval and the treatment cannot be either discontinued&#xD;
             or switched to a different medication prior to starting study drug.&#xD;
&#xD;
          2. Other concurrent severe and/or uncontrolled medical conditions:&#xD;
&#xD;
             Patients with another primary malignant disease, except those that do not currently&#xD;
             require treatment; acute or chronic liver, pancreatic or severe renal disease; another&#xD;
             severe and/or life-threatening medical disease.&#xD;
&#xD;
          3. Patients who are: (a) pregnant, (b) breast feeding, (c) of childbearing potential&#xD;
             without a negative pregnancy test prior to baseline and (d) male or female of&#xD;
             childbearing potential unwilling to use contraceptive precautions throughout the trial&#xD;
             (post-menopausal women must be amenorrheic for at least 12 months to be considered of&#xD;
             non-childbearing potential).&#xD;
&#xD;
          4. Who is known human deficiency virus (HIV) positive.&#xD;
&#xD;
          5. Use of any other investigational agent in the last 30 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianxiang Wang, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Hematology &amp; Blood Diseases Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Hematology &amp; Blood Diseases Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 5, 2015</study_first_submitted>
  <study_first_submitted_qc>August 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2015</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Hematology &amp; Blood Diseases Hospital</investigator_affiliation>
    <investigator_full_name>wang, jianxiang</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Acute</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoid</keyword>
  <keyword>Philadelphia chromosome</keyword>
  <keyword>dasatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

